LV12979B - Pharmaceutical composition - Google Patents

Pharmaceutical composition Download PDF

Info

Publication number
LV12979B
LV12979B LVP-01-134A LV010134A LV12979B LV 12979 B LV12979 B LV 12979B LV 010134 A LV010134 A LV 010134A LV 12979 B LV12979 B LV 12979B
Authority
LV
Latvia
Prior art keywords
gbb
thp
butyrobetaine
gamma
pharmaceutical composition
Prior art date
Application number
LVP-01-134A
Other languages
English (en)
Inventor
Ivars Kalvins
Maris Veveris
Anatolijs Birmans
Original Assignee
Ivars Kalvins
Maris Veveris
Anatolijs Birmans
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ivars Kalvins, Maris Veveris, Anatolijs Birmans filed Critical Ivars Kalvins
Priority to LVP-01-134A priority Critical patent/LV12979B/en
Priority to AT02702955T priority patent/ATE350029T1/de
Priority to SI200230507T priority patent/SI1429753T1/sl
Priority to JP2003526391A priority patent/JP4382480B2/ja
Priority to PCT/LV2002/000004 priority patent/WO2003022262A1/en
Priority to IL16073402A priority patent/IL160734A0/xx
Priority to CA2459719A priority patent/CA2459719C/en
Priority to PT02702955T priority patent/PT1429753E/pt
Priority to EA200400386A priority patent/EA006675B1/ru
Priority to US10/488,840 priority patent/US20040242590A1/en
Priority to NZ532178A priority patent/NZ532178A/en
Priority to KR1020047003366A priority patent/KR100841035B1/ko
Priority to DE60217369T priority patent/DE60217369T2/de
Priority to PL02368758A priority patent/PL368758A1/xx
Priority to AU2002236340A priority patent/AU2002236340B2/en
Priority to CNB028175077A priority patent/CN1275595C/zh
Priority to EP02702955A priority patent/EP1429753B1/en
Priority to DK02702955T priority patent/DK1429753T3/da
Priority to ES02702955T priority patent/ES2280505T3/es
Priority to MXPA04002050A priority patent/MXPA04002050A/es
Priority to MYPI20023224A priority patent/MY134074A/en
Priority to ARP020103331A priority patent/AR036423A1/es
Priority to TW091120239A priority patent/TWI224506B/zh
Priority to JO200291A priority patent/JO2507B1/en
Publication of LV12979B publication Critical patent/LV12979B/en
Priority to IL160734A priority patent/IL160734A/en
Priority to CU20040040A priority patent/CU23347B6/es
Priority to MA27608A priority patent/MA27683A1/fr
Priority to ZA200402702A priority patent/ZA200402702B/en
Priority to BG108673A priority patent/BG108673A/xx
Priority to HR20040328A priority patent/HRPK20040328B3/xx
Priority to HK05100218A priority patent/HK1068003A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (7)

  1. LV 12979 IZGUDROJUMA FORMULA 1. Gamma-butirobetaīna vai tā farmaceitiski pieņemamas sāls pielietojums medikamenta ražošanā, kas paredzēts zīdītāju seksuālās aktivitātes un potences normalizēšanai un stimulēšanai.
  2. 2. Farmaceitiskā kompozīcija zīdītāju seksuālās aktivitātes un potences normalizēšanai un stimulēšanai, kas satur gamma-butirobetaīnu kopā ar farmaceitiski pieņemamu atšķaidītāju vai nesēju.
  3. 3. Farmaceitiskā kompozīcija pēc 2. punkta, kas papildus ietver 3-(2,2,2-trimetil)hidrazīnija propionātu vai tā farmaceitiski pieņemamu sāli.
  4. 4. Farmaceitiskā kompozīcija pēc 2. punkta, kas papildus ietver fosfodiesterāzes inhibitocu.
  5. 5. Farmaceitiskā kompozīcija pēc 4. punkta, kurā minētais fosfodiesterāzes inhibitors ir V tipa inhibitors.
  6. 6. Farmaceitiskā kompozīcija pēc 5. punkta, kurā minētais V tipa fosfodiesterāzes inhibitors ir ņemts no rindas: sildenafils, vardenafils un cialis.
  7. 7. Farmaceitiskās kompozīcijas pēc jebkura no 2. līdz 6. punktam pielietojums medikamenta ražošanā, kas paredzēts zīdītāju seksuālās aktivitātes un potences normalizēšanai un stimulēšanai.
LVP-01-134A 2001-09-07 2001-09-07 Pharmaceutical composition LV12979B (en)

Priority Applications (31)

Application Number Priority Date Filing Date Title
LVP-01-134A LV12979B (en) 2001-09-07 2001-09-07 Pharmaceutical composition
JP2003526391A JP4382480B2 (ja) 2001-09-07 2002-03-04 γ−ブチロベタインを含んで成る医薬組成物
DK02702955T DK1429753T3 (da) 2001-09-07 2002-03-04 Farmaceutisk sammensætning omfattende gamma-butyrobetain
CNB028175077A CN1275595C (zh) 2001-09-07 2002-03-04 含有γ－三甲铵基丁内盐的药物组合物
PCT/LV2002/000004 WO2003022262A1 (en) 2001-09-07 2002-03-04 Pharmaceutical composition comprising gamma-butyrobetaine
IL16073402A IL160734A0 (en) 2001-09-07 2002-03-04 Pharmaceutical composition comprising gamma-butyrobetaine
CA2459719A CA2459719C (en) 2001-09-07 2002-03-04 Pharmaceutical composition comprising gamma-butyrobetaine
PT02702955T PT1429753E (pt) 2001-09-07 2002-03-04 Composição farmacêutica que compreende gama-butirobetaína
EA200400386A EA006675B1 (ru) 2001-09-07 2002-03-04 Фармацевтическая композиция, содержащая гамма-бутиробетаин
US10/488,840 US20040242590A1 (en) 2001-09-07 2002-03-04 Pharmaceutical composition comprising gamma-butyrobetaine
NZ532178A NZ532178A (en) 2001-09-07 2002-03-04 Pharmaceutical composition comprising gamma-butyrobetaine for treating erectile dysfunction
KR1020047003366A KR100841035B1 (ko) 2001-09-07 2002-03-04 감마-부티로베타인을 포함하여 이루어지는 약제학적 조성물
SI200230507T SI1429753T1 (sl) 2001-09-07 2002-03-04 Farmacevtski sestavek, ki vsebuje gama-butirobetain
PL02368758A PL368758A1 (en) 2001-09-07 2002-03-04 Pharmaceutical composition comprising gamma-butyrobetaine
AU2002236340A AU2002236340B2 (en) 2001-09-07 2002-03-04 Pharmaceutical composition comprising gamma-butyrobetaine
AT02702955T ATE350029T1 (de) 2001-09-07 2002-03-04 Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain
EP02702955A EP1429753B1 (en) 2001-09-07 2002-03-04 Pharmaceutical composition comprising gamma-butyrobetaine
DE60217369T DE60217369T2 (de) 2001-09-07 2002-03-04 Pharmazeutische zusammensetzung enthaltend gamma-butyrobetain
ES02702955T ES2280505T3 (es) 2001-09-07 2002-03-04 Composicion farmaceutica que comprende gamma-butirobetaina.
MXPA04002050A MXPA04002050A (es) 2001-09-07 2002-03-04 Composicion farmaceutica comprendiendo gamma-butirobetaina.
MYPI20023224A MY134074A (en) 2001-09-07 2002-08-29 Pharmaceutical composition comprising gamma-butyrobetaine for treatment of impotence
ARP020103331A AR036423A1 (es) 2001-09-07 2002-09-04 Composicion farmaceutica.
JO200291A JO2507B1 (en) 2001-09-07 2002-09-05 Pharmaceutical preparation
TW091120239A TWI224506B (en) 2001-09-07 2002-09-05 Pharmaceutical composition
IL160734A IL160734A (en) 2001-09-07 2004-03-04 Pharmaceutical preparation containing gamma-butyrobtaine and its use
CU20040040A CU23347B6 (es) 2001-09-07 2004-03-04 Composición farmacéutica que comprende gamma-butirobetaína
MA27608A MA27683A1 (fr) 2001-09-07 2004-04-05 Composition pharmaceutique contenant de la gamma-butyrobetaine.
ZA200402702A ZA200402702B (en) 2001-09-07 2004-04-06 Pharmaceutical composition comprising gamma-butyrobetaine.
BG108673A BG108673A (en) 2001-09-07 2004-04-07 Pharmaceutical composition comprising gamma-butyrobetaine
HR20040328A HRPK20040328B3 (en) 2001-09-07 2004-04-07 Pharmaceutical composition comprising gamma-butyrobetaine
HK05100218A HK1068003A1 (en) 2001-09-07 2005-01-11 Pharmaceutical composition comprising gamma-butyrobetaine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LVP-01-134A LV12979B (en) 2001-09-07 2001-09-07 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
LV12979B true LV12979B (en) 2003-05-20

Family

ID=19735292

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-01-134A LV12979B (en) 2001-09-07 2001-09-07 Pharmaceutical composition

Country Status (30)

Country Link
US (1) US20040242590A1 (lv)
EP (1) EP1429753B1 (lv)
JP (1) JP4382480B2 (lv)
KR (1) KR100841035B1 (lv)
CN (1) CN1275595C (lv)
AR (1) AR036423A1 (lv)
AT (1) ATE350029T1 (lv)
AU (1) AU2002236340B2 (lv)
BG (1) BG108673A (lv)
CA (1) CA2459719C (lv)
CU (1) CU23347B6 (lv)
DE (1) DE60217369T2 (lv)
DK (1) DK1429753T3 (lv)
EA (1) EA006675B1 (lv)
ES (1) ES2280505T3 (lv)
HK (1) HK1068003A1 (lv)
HR (1) HRPK20040328B3 (lv)
IL (2) IL160734A0 (lv)
JO (1) JO2507B1 (lv)
LV (1) LV12979B (lv)
MA (1) MA27683A1 (lv)
MX (1) MXPA04002050A (lv)
MY (1) MY134074A (lv)
NZ (1) NZ532178A (lv)
PL (1) PL368758A1 (lv)
PT (1) PT1429753E (lv)
SI (1) SI1429753T1 (lv)
TW (1) TWI224506B (lv)
WO (1) WO2003022262A1 (lv)
ZA (1) ZA200402702B (lv)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10325813B4 (de) * 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
LV13450B (en) * 2004-08-24 2006-11-20 Grindeks As Novel medicinal use of meldonium and pharmaceutical compositions thereof
EP1909576A4 (en) 2005-07-29 2010-09-01 Concert Pharmaceuticals Inc NEW PHARMACEUTICAL COMPOUNDS
WO2009095445A1 (en) * 2008-01-29 2009-08-06 Grindeks New second medical use of 3-(2,2,2-trimethylhydrazine)propionate dihydrate
CN101781302B (zh) * 2009-05-31 2013-07-10 段波 一种磷酸二酯酶抑制剂和异黄酮形成的加成物及其应用
RU2622757C1 (ru) * 2016-06-02 2017-06-19 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) Способ лечения эректильной дисфункции

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1198434B (it) * 1981-01-06 1988-12-21 Sigma Tau Ind Farmaceuti Composizione farmaceutica comprendente gamma butirrobetaina per il trattamento di sindromi da carenze di carnitina
LV11727B (en) * 1995-08-21 1997-08-20 Kalvins Ivars Pharmaceutical composition
LV11728B (en) * 1995-08-21 1997-08-20 Kalvins Ivars Pharmaceutical composition

Also Published As

Publication number Publication date
JP2005504071A (ja) 2005-02-10
JP4382480B2 (ja) 2009-12-16
DK1429753T3 (da) 2007-05-14
KR20040034704A (ko) 2004-04-28
AU2002236340B2 (en) 2008-06-12
JO2507B1 (en) 2009-10-05
HRPK20040328B3 (en) 2006-02-28
MA27683A1 (fr) 2006-01-02
PL368758A1 (en) 2005-04-04
EA200400386A1 (ru) 2004-08-26
AR036423A1 (es) 2004-09-08
MXPA04002050A (es) 2004-06-07
HK1068003A1 (en) 2005-04-22
IL160734A (en) 2009-09-22
DE60217369D1 (de) 2007-02-15
ES2280505T3 (es) 2007-09-16
ATE350029T1 (de) 2007-01-15
PT1429753E (pt) 2007-04-30
HRP20040328A2 (en) 2004-08-31
US20040242590A1 (en) 2004-12-02
CA2459719C (en) 2010-07-06
CN1275595C (zh) 2006-09-20
KR100841035B1 (ko) 2008-06-24
EP1429753B1 (en) 2007-01-03
SI1429753T1 (sl) 2007-06-30
MY134074A (en) 2007-11-30
EP1429753A1 (en) 2004-06-23
EA006675B1 (ru) 2006-02-24
CN1551764A (zh) 2004-12-01
TWI224506B (en) 2004-12-01
DE60217369T2 (de) 2007-08-23
IL160734A0 (en) 2004-08-31
CU23347B6 (es) 2009-02-20
ZA200402702B (en) 2005-05-11
NZ532178A (en) 2007-05-31
BG108673A (en) 2005-03-31
CA2459719A1 (en) 2003-03-20
WO2003022262A1 (en) 2003-03-20

Similar Documents

Publication Publication Date Title
JP2925326B2 (ja) ヒトの窒素保持の促進方法
KR101302838B1 (ko) 진성 당뇨병 치료용 로플루밀라스트
WO1991007188A1 (en) Method for reducing blood cholesterol using arginine
JP2015007096A (ja) 運動障害の予防および／または治療剤
US20030187055A1 (en) Synergistic pharmaceutical combinations for treating obesity
CA2459719C (en) Pharmaceutical composition comprising gamma-butyrobetaine
US3557292A (en) Compositions and methods for treating parkinson's disease with combinations of l-3,4-dihydroxyphenylalanine and a hydrazine
AU2002236340A1 (en) Pharmaceutical composition comprising gamma-butyrobetaine
LV12978B (en) Pharmaceutical composition
US3150044A (en) Treatment and composition for high blood pressure and palpitation
WO2017144978A1 (ru) Соли (1r,2r,3s)-3-(3,4-дихлорфенил)-2-(этоксиметил)-8-метил-8-азабицикло [3.2.1]октана и оптически активных ацетиламинокислот, их применение для лечения ожирения
US3298916A (en) Treatment and composition for high blood pressure and palpitation
KR20110006424A (ko) 아데포비어 다이피복실 및 아세틸-ｌ-카르니틴을 포함하는 약제학적 조성물
RU2165759C1 (ru) Средство для лечения алкогольной интоксикации
US20050009919A1 (en) Treating cachexia and excessive catabolism with (-)-hydroxycitric acid
WO2023156275A1 (en) Pharmaceutical composition and medicament comprising l-tryptophan, l-5-hydroxytryptophan and a peripheral degradation inhibitor
JP2527958B2 (ja) 中枢神経障害治療剤
JPH06102624B2 (ja) 非心臓由来の不整脈防止薬
JPH0440328B2 (lv)
JPH09132553A (ja) ドーパミンまたはＬ−ドーパのｎ−３系不飽和脂肪酸誘導体
WO2016075539A1 (ru) Композиция для лечения нарушений, связанных с избыточным весом или ожирением
EA026727B1 (ru) Соль (1r,2r,3s)-3-(3,4-дихлорфенил)-2-(этоксиметил)-8-метил-8-азабицикло[3.2.1]октана и фталевой кислоты, способ её получения, продукт способа, фармацевтические композиции для лечения и/или профилактики нарушений, связанных с ожирением, их применение и способы лечения и/или профилактики нарушений, связанных с ожирением
UA48470A (uk) Біологічно активний препарат "кардонат"